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Abstract: Fractionation of the ethyl acetate extract of the marine bacterium Bacillus 
pumilus isolated from the black coral Antipathes sp. led to the isolation of five compounds: 
cyclo-(L-Leu-L-Pro) (1), 3-hydroxyacetylindole (2), N-acetyl--oxotryptamine (3),  
cyclo-(L-Phe-L-Pro) (4), and 3-formylindole (5). The structures of compounds 1−5 were 
established by spectroscopic analyses, including HRESITOF-MS and NMR (1H, 13C, 
HSQC, HMBC and COSY). Compounds 2, 3 and 5 caused the inhibition on the growth of 
Trypanosoma cruzi (T. cruzi), with IC50 values of 20.6, 19.4 and 26.9 μM, respectively, 
with moderate cytotoxicity against Vero cells. Compounds 1−5 were found to be inactive 
when tested against Plasmodium falciparum and Leishmania donovani, therefore showing 
selectivity against T. cruzi parasites. 
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1. Introduction 
Chagas disease, also known as American trypanosomiasis, is a tropical neglected disease that 
largely affects populations in Latin America, where the disease is endemic. An estimated 10,000 
people died in 2008 from the disease and more than 25 million people are at risk of infection [1]. 
This illness occurs in two phases. The initial or acute phase takes about two months post-infection. 
In most of the cases symptoms are either absent or mild. Less than 50% of people only display a skin 
lesion or purple swollen eyelids on an eye. During the second or chronic phase, as many as 30% of 
patients develop heart disease, and up to 10% of patients develop gastrointestinal disturbances, 
neurological problems or a combination of both. In subsequent years the infection may result in sudden 
death or heart failure due to progressive destruction of the heart muscle [2]. 
Current treatment against Chagas disease is based on toxic chemotherapeutic agents, specifically 
benznidazole and nifurtimox, which have many serious side effects. Both drugs are almost 100% 
effective during the acute phase. Nevertheless, their effectiveness decreases significantly during the 
chronic phase. Moreover, apart from the adverse reactions that usually arise with them (incidence of 
up to 40% of patients) [2,3], the treatment is long in duration, increasing patients’ non-compliance. 
The poor therapeutic options available for the treatment of Chagas disease demand an urgent search 
and development of new and more effective anti-Trypanosoma cruzi (anti-T. cruzi) drugs. In this 
regard, natural products offer a diversity of possibilities for drug discovery against Chagas disease. To 
date most of the efforts have focused on plant metabolites [4–6]. However, the marine environment 
remains largely unexplored as a resource for antitrypanosomal compounds. A few examples found in  
a literature search on marine organisms producing anti-T. cruzi metabolites include sponges [7–9], 
tunicates [10], fungi [11,12] and marine cyanobacteria [13–15]. Remaining marine taxa, including 
heterotrophic bacteria, remain untapped as a source of compounds against Chagas disease. 
Among marine heterotrophic bacteria, the genus Bacillus has been explored for its potential to 
produce active secondary metabolites. Most of the compounds isolated from this genus, including 
macrolides [16–18], diketopiperazines [19], lipoamides [20] and fatty acids [21], showed antimicrobial 
activity. Moreover other Bacillus metabolites belonging to the cyclopeptides [22–24], isocoumarins [25] 
and thiazole alkaloids [26] structural classes showed anticancer, antimalarial and algicidal activity, 
respectively. No anti-T. cruzi compounds have been reported from the genus Bacillus. 
This work was designed to investigate the potential of heterotrophic bacteria associated with 
Panamanian corals as a source of antiprotozoal compounds. Herein we report the isolation, 
identification and anti-parasitic activity of compounds produced by the bacterium Bacillus pumilus 
isolated from the black coral Antiphates sp, collected near Otoque Island, Pacific coast of Panama. 
2. Results and Discussion 
2.1. Collection and Identification of Biological Material 
The strain GL0057 was isolated from the mucus of the black coral Antiphates sp. collected near 
Otoque Island in the Golf of Panama (Pacific Ocean). The bacterium was identified based on its 16S 
rRNA sequence which showed 99% similarity to Bacillus pumilus when compared with sequences 
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deposited in BLAST-NCBI database. The sequence of strain GL0057 was deposited in GenBank under 
accession number JX569793. 
2.2. Extraction, Isolation and Structural Elucidation of Compounds 
Strain GL0057 was cultured in 10 L liquid media and extracted with ethyl acetate to obtain the 
organic crude extract. The extract was fractionated using C-18 solid phase extraction cartridges (SPE) 
followed by HPLC purification obtaining and identifying the following compounds: cyclo-(L-Leu-L-Pro) 
(1) [27], 3-hydroxyacetylindole (2) [28], N-acetyl--oxotryptamine (3) [29], cyclo-(L-Phe-L-Pro) (4) [27], 
and 3-formylindole (5) [30] (Figure 1). Structures of compounds 1–5 were defined by spectroscopic 
analysis including HRESITOF-MS, 1H-NMR, 13C-NMR and optical rotations, and we found them to 
be metabolites previously reported in the literature. NMR assignments for compounds 2, 3 and 5 were 
confirmed by 2D-NMR experiments including HSQC, HMBC and COSY. 
Figure 1. Chemical structures of metabolites produced by Bacillus pumilus. 
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Compound 3 was isolated as an amorphous white solid. HRESITOF-MS showed a pseudomolecular 
ion peak [M+Na]+ at m/z 239.0790, corresponding with the molecular formula C12H12N2O2Na (calcd. 
for C12H12N2O2Na, 239.0791). The 1H-NMR spectrum showed characteristic chemical shifts of a  
mono-substituted indole nucleus at δH 7.25 (2H, m, H-5, H-6), 7.48 (1H, m, H-7), 8.24 (1H, bs, H-4) 
and 8.26 (1H, m, H-2), in addition to one methylene group attached to a nitrogen at δ 4.62 (2H, s) and 
one acetate methyl group at δH 2.11 ppm (3H, s, H-5′). The 13C-NMR spectrum showed resonances for 
12 carbon atoms. DEPT experiments revealed the presence of two quaternary carbonyls at δC 192.7  
(C-8) and 174.5 ppm (C-10), three sp2 quaternary carbons at δC 139.1 (C-7a), 127.8 (C-3a), 116.7  
(C-3); five sp2 methines at δC 127.8 (C-2), 125.3 (C-6), 124.2 (C-5), 123.5 (C-4), 113.8 (C-7); and the 
presence of a methylene and a methyl group at δc 47.9 ppm and 23.3 ppm, respectively. The spin 
system formed by protons H-4 to H-7 was confirmed by COSY experiments.  
The connection of the oxoethyl moiety to the indole nucleus was confirmed through 2,3J HMBC 
correlations observed between H-2′ (δH 4.62) and carbon C-3. The connection between the acetamide 
group to the oxoethyl was also confirmed through 2,3J HMBC correlations between H-2′ and C-4′  
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(δc 174.5 ppm). The presence of an exchangeable amide proton was evidenced by measuring of the 
1H-NMR spectrum in deuterated methanol and chloroform. Therefore, compound 3 was identified as 
N-acetyl-β-oxotryptamine by its NMR data and comparison with the published data in the literature [29]. 
The NMR data of compounds 2 and 5 showed similar spectroscopic features as compound 3,  
the main differences being found in the length of the side chain. Thus, compound 3 contained an 
oxoethyl-acetamide group, while compounds 2 and 5 contained a hydroxyacetyl (δc 195.8, C-1′; 66.1, 
C-2′, δH 4.75, H-2′) and formyl (δc 188.3, C-1′; δH 9.88, s, H-1′) groups, respectively. 
2.3. Antiparasitic Activity 
Compounds 1−5 were tested for activity against parasites causative of three neglected tropical 
diseases: Leishmania donovani, Trypanosoma cruzi (T. cruzi) and Plasmodium falciparum. Indole 
alkaloids 2, 3 and 5 selectively inhibited the growth of T. cruzi, being inactive against P. falciparum and 
L. donovani (Table 1). Diketopiperazines 1 and 4 were inactive against all parasites. Compounds 1, 3 
and 5 showed no significant cytotoxicity when evaluated against African Green Monkey kidney 
epithelial (Vero) cells displaying IC50 values of 149, 66 and 87 µM, respectively. 
Table 1. Biological activity (IC50 µM) of 1–5 against tropical parasites. 
Compounds L. donovani P. falciparum T. cruzi a 
Cyclo-(L-Leu-L-Pro) (1) I I I 
3-Hydroxyacetylindole (2) I I 20.6 
N-acetyl--oxotryptamine (3) I I 19.4 
Cyclo-(L-Phe-L-Pro) (4) I I I 
3-Formylindole (5) I I 26.9 
Nifurtimox   1.6 
I, Inactive at 10 µg/mL; a Values for T. cruzi are the average of two experiments with two replicates each. 
Given the structural similarities and biological activity among compounds 2, 3 and 5, the length and 
substitution of the side chain attached to carbon C-3 does not appear to produce a significant difference 
in the biological activity. However, if we compare compound 2 with the structure of tryptophol (6), 
which also showed some antitrypanosomal activity (IC50 30.6 µM) [31], it can be inferred that the 
presence of an electron-attracting group in the side chain, like the carbonyl at C-1′, enhances the 
biological activity. This observation could be a starting point for designing new analogs based on the 
activity of these alkaloids. 
3. Experimental 
3.1. General Procedures 
Optical rotations were measured with a Jasco P-2000 polarimeter. NMR spectra were acquired on a 
Jeol Eclipse 400 MHz spectrometer and are referenced to residual solvent 1H and 13C signals (δH 7.26, 
δC 77.0 for CDCl3). Low-resolution ESI-MS were acquired on Jeol LC-mate mass spectrometer, while 
high-accuracy mass measurements were obtained on an Agilent 6230 mass spectrometer. The 
purification of the compounds was carried out on Agilent 1100 HPLC system equipped with a 
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quaternary pump, a diode array detector, and a reverse phase silica gel column (Phenomenex Synergi 
Hydro-RP, 250 mm × 100 mm, 4 μm) at a flow rate of 1.0 mL/min. Pre-fractionation of the extract was 
carried out using SupelcleanTM C-18 solid phase extraction (SPE) tubes. TLC was performed on 
precoated silica gel 60 F254 plates (Merck). All solvents were HPLC grade and used without  
further purification. 
3.2. Biological Material Collection and Identification 
A healthy specimen of the black coral Antipathes sp. was collected by hand using SCUBA near 
Otoque Island in the Pacific Ocean off the coast of Panama in August 2009. For the isolation of  
coral-associated bacteria, a small piece of the coral was rinsed with sterile seawater to remove loosely 
attached bacteria, and a small portion of the coral mucus was inoculated on Petri dishes with  
seawater-based nutrient media. Agar plates were taken to the laboratory and observed for bacterial 
isolation, at room temperature over the period of one month. Strain GL0057 was further isolated from 
the collection plate and successively re-plated until a pure strain was obtained. Coral was identified as 
Antiphates sp. based on its morphology and SEM-micrographs of the coral sclerites by Dr. Hector 
Guzman from the Smithsonian Tropical Research Institute. Taxonomy of the strain GL0057 was 
carried out by sequencing of the 1409 bp of 16S rRNA gene. The gene sequence was submitted to 
NCBI-BLAST database and showed 99% similarity to 16S rRNA gene sequence of a strain identified 
as Bacillus pumilus. Reference specimens of the coral GLOT-120209-03 and the bacterial strain 
GL0057 are deposited at INDICASAT’s Center for Biodiversity and Drug Discovery. 
3.3. Fermentation and Extraction 
The bacterium Bacillus pumilus was inoculated in ten Erlenmeyer flasks (1 L), containing 500 mL 
of seawater-based liquid medium (10 g of starch of potatoes, 4 g of yeast extract and 2 g of peptone in 
1 L of natural sea water). All reagents for the culture media were purchased from Sigma. Erlenmeyer 
flasks were placed in an orbital shaker at 172 rpm at room temperature for 10 days. After this period, 
the culture broth was extracted with ethyl acetate (2 L × 3). The organic extract was washed with 
distillated water (2 L × 3) in order to remove traces of culture media from the organic extract. The 
extract was then dried under reduced pressure to obtain 456 mg of solid. 
3.4. Isolation of Alkaloids 
Extract (456 mg) was fractionated using C-18 solid phase extraction (SPE) cartridges eluted with a 
stepwise gradient of 20%, 40%, 50%, 60%, 70%, 80%, 90%, and 100% of methanol in water to yield 
eight fractions (F1-F8). Fractions F1 to F8 were analyzed by NMR spectroscopy and fraction F2 
(eluted with 40% of methanol in water) showed the presence of secondary metabolites in its 1H-NMR 
spectrum. Therefore, fraction F2 was purified by reverse phase HPLC (Synergi Hydro 250 × 10 mm 
column, isocratic elution of 85% methanol-15% distillated water, UV detector at 254 nm, flow of  
1.0 mL/min) to afford 1.8 mg of cyclo-(L-Phe-L-Pro) (1), 0.8 mg of 3-hydroxyacetylindole (2), 0.9 mg 
of N-acetyl-β-oxotryptamine (3), 1.4 mg of cyclo-(L-Leu-L-Pro) (4), and 1.0 mg of 3-formylindole (5). 
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3.5. Spectral Data 
3-Hydroxyacetylindole (2). Colorless solid; 1H-NMR (CD3OD): δ: 8.25 (1H, m, H-4), 8.23 (1H, bs,  
H-2), 7.48 (1H, m, H-7), 7.25 (2H, m, H-5, H-6), 4.75 (2H, s, CH2-2′); 13C-NMR (CD3OD): δ: 195.8 
(C-1′), 138.1 (C-7a), 133.8 (C-2), 126.8 (C-3a), 124.2 (C-6), 123.1 (C-5), 122.5 (C-4), 118.7 (C-3), 
112.8 (C-7), 66.1 (C-2′); HRESITOF-MS m/z 198.0527 [M+Na]+ (C10H9NO2Na requires 198.0525).  
N-Acetyl-β-oxotryptamine (3). Withe solid; 1H-NMR (CD3OD): δ: 8.26 (1H, bs, H-2), 8.24 (1H, m,  
H-4), 7.48 (1H, m, H-7), 7.25 (2H, m, H-5, H-6), 4.62 (2H, s, CH2-2′), 2.11 (3H, s, CH3-5′); 13C-NMR 
(CD3OD): δ: 192.7 (C-1'), 174.5 (C-4′), 139.1 (C-7a), 135.1 (C-2), 127.8 (C-3a), 125.3 (C-6), 124.2  
(C-5), 123.5 (C-4), 116.7 (C-3), 113.8 (C-7), 47.9 (C-2′), 23.3 (C-5′); HRESITOF-MS m/z 239.0790 
[M+Na]+ (C12H12N2O2 Na requires 239.0791). 
3-Formylindole (5). Colorless solid; 1H-NMR (CD3OD): δ: 9.88 (1H, d, J = 2.9, H-1′), 8.25 (1H, m,  
H-4), 8.23 (1H, bs, H-2), 7.48 (1H, m, H-7), 7.25 (2H, m, H-5, H-6); 13C-NMR (CD3OD): δ: 188.3  
(C-1′), 138.3 (C-2), 136.4 (C-7a), 123.6 (C-3a), 122.3 (C-6), 122.3 (C-5), 121.0 (C-4), 118.8 (C-3), 
111.8 (C-7); HRESITOF-MS m/z 146.0601 [M+H]+ (C9H8NO requires 146.0600).  
3.6. In Vitro Biological Activity 
3.6.1. Plasmodium falciparum Bioassay 
Antiplasmodial activity was evaluated using a fluorometric method based on the detection of 
parasite DNA with the fluorochrome PicoGreen using a chloroquine-resistant strain (Indochina W2) of  
P. falciparum. The samples were considered inactive if they inhibited less than 75% of the growth of 
parasites as compared to their untreated controls at 10 µg/mL [32]. 
3.6.2. Leishmania donovani Bioassay 
Axenically grown (cell free) amastigotes of L. donovani were used to assess parasite growth and 
survival, in the presence of the compounds. Samples were tested in duplicate at 10 µg/mL. The results 
were expressed as a percentage of growth inhibition (GI) compared to untreated controls. Samples that 
showed below 75% GI were considered inactive [33]. 
3.6.3. Trypanosoma cruzi Bioassay 
T. cruzi bioassays were performed using a colorimetric method, and the inhibition of parasite 
growth was assessed by the expression of the reporter gene for beta-galactosidase (β-Gal) in the 
recombinant Tulahuen clone C4 of T. cruzi. Assays were performed in duplicate on amastigotes, the 
intracellular form of the parasite infecting African green monkey kidney (Vero) cells, exposed during 
five days to different concentrations (10, 2, 0.4, 0.08 and 0.016 μg/mL) of the test compounds at 37 °C 
under an atmosphere of 5% CO2/95% air. The resulting color from the cleavage of chlorophenol  
red-β-D-galactoside (CPRG) by β-Gal expressed by the parasite was measured at 570 nm. The 
concentration that inhibited 50% of the parasites growth (IC50) was calculated through the inhibition 
Molecules 2012, 17 11152 
 
 
curve of the obtained optical density values, and compared to the untreated controls. Nifurtimox was used 
as a positive control (IC50 0.15–13.4 µM) [34,35]. 
3.6.4. Cytotoxicity Bioassay 
Vero cells were seeded in 96-well plates in RPMI 1640 medium supplemented with 10% FBS and 
1% penicillin/streptomycin. The cells were allowed to grow for 24 hours before adding the test 
compounds, dissolved in DMSO, to final concentrations of 10, 4, 0.2 and 0.08 µg/mL. A negative control 
(with same volume of DMSO - added to the samples) was placed in all plates. Samples were incubated 
for five days before staining and examining for reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) and analyzed 4 hours later in a color plate reader at 570 nm [36]. 
4. Conclusions 
Five compounds were isolated from the marine bacterium Bacillus pumilus including three indole 
alkaloids: 3-hydroxyacetylindole (2), N-acetyl--oxotryptamine (3) and 3-formylindole (5) that 
showed activity against T. cruzi. Compounds 2, 3 and 5 showed no activity against P. falciparum and 
L. donovani, indicating their selectivity against T. cruzi parasites. Even thought alkaloids isolated in 
this work have been also reported from other sources different than marine bacteria; to our knowledge 
they constitute the first example of antitrypanosomal secondary metabolites isolated from marine 
heterotrophic bacteria. Given that there have not been new alternatives for the treatment of Chagas 
disease in half a century, the search for new antitrypanosomal compounds is of outmost importance to 
global programs against neglected diseases. 
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